(Q37202758)

18 August 2017

1 reference

title

Docetaxel in the management of patients with head and neck squamous cell carcinoma (English)

1 reference

head and neck squamous cell carcinoma

18 August 2017

main subject

0 references

1 reference

Jacques Bernier

1

1 reference

18 August 2017

Conny Vrieling

series ordinal

2

1 reference

18 August 2017

publication date

1 July 2008

1 reference

Expert Review of Anticancer Therapy

18 August 2017

published in

1 reference

18 August 2017

volume

8

1 reference

18 August 2017

issue

7

1 reference

18 August 2017

page(s)

1023-1032

1 reference

Global cancer statistics, 2002

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Promotion of microtubule assembly in vitro by taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

End points for new agents in induction chemotherapy for locally advanced head and neck cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Radiotherapy with concomitant weekly docetaxel for Stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC Phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1023

10.1586/14737140.8.7.1023

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference